Vor Biopharma Inc.

0.76
0.06 (8.26%)
At close: Apr 23, 2025, 3:59 PM
0.76
0.10%
Pre-market: Apr 24, 2025, 09:27 AM EDT
8.26%
Bid 0.75
Market Cap 94.45M
Revenue (ttm) n/a
Net Income (ttm) -116.91M
EPS (ttm) -1.7
PE Ratio (ttm) -0.44
Forward PE -0.78
Analyst Buy
Ask 0.77
Volume 320,103
Avg. Volume (20D) 329,909
Open 0.75
Previous Close 0.70
Day's Range 0.75 - 0.84
52-Week Range 0.49 - 1.87
Beta -0.21

About VOR

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, an...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 159
Stock Exchange NASDAQ
Ticker Symbol VOR
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for VOR stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 1354.06% from the latest price.

Stock Forecasts
3 months ago
+51.55%
Vor Bio shares are trading higher after the compan... Unlock content with Pro Subscription
4 months ago
+26.89%
Vor Biopharma shares are trading higher after the company announced it will present data on its AML therapy at the ASH 2024 annual meeting.